Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product
Key facts
- Who runs it
- Becton, Dickinson and Company
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 394 people enrolled
- Started
- 26 Jun 2024
- Ended
- 23 Oct 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- test Aerobic/F Culture Vials
- control Aerobic/F Culture Vials
- Record updated
- 20 November 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Subject is willing to provide written informed consent to sponsor
- Blood specimens
- Patients with suspected blood infection that have one or more of the following characteristics :; Body temperature > 38°C or body temperature <36°C; b) chills; c) increased peripheral blood leukocyte count (count > 10.0×109/L, especially if there is a "left shift") or decrease (count < 3.0×109/L); d) Respiratory rate > 20 beats/min or arterial partial pressure of carbon dioxide (PaCO2) <32mmHg; e) Heart rate> 90 beats/min; f) mucocutaneous hemorrhage; g) coma; h) Multi-organ dysfunction; i) decreased blood pressure; j) Elevated inflammatory response parameters such as C-reactive protein or hypersensitive C-reactive protein, procalcitonin (PCT), 1,3-β-D-glucan (G test), etc
Who cannot take part
- Patients with severe and very severe anemia (last hemoglobin <60g/L within seven days)
- Subjects have been enrolled in this study and samples have been collected
- Females with known pregnancy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a multi-center, randomized clinical validation. Subjects should be fully informed of this protocol and related risks, and can only be enrolled into this study after signing the informed consent form. Blood collection of the subjects at the same puncture point at a single site will be injected into the test vial and the control vial respectively, and the vials will be transferred to the BACTEC system for culture and the results will be observed. After the BACTEC system incubation completion, the vials will be subcultured. Strains grown on plates will be identified using appropriate methods and, if possible, at the species level.
The 2 groups in the trial
- BD BACTEC™ Plus Aerobic/F Culture Vials(test)
Additional blood sample collected compared to clinical routine care
Treatment: test Aerobic/F Culture Vials
- BD BACTEC™ Plus Aerobic/F Culture Vials(control)
clinical routine care
Treatment: control Aerobic/F Culture Vials
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 20 November 2025